Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3107 views | HTML 3539 views | ?
Michela Capello1,2,7,*, Sammy Ferri-Borgogno1,2,8,*, Chiara Riganti3, Michelle Samuel Chattaragada1,2, Moitza Principe1,2, Cecilia Roux1,2, Weidong Zhou4, Emanuel F. Petricoin4, Paola Cappello1,2,5, Francesco Novelli1,2,5,6
1Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin 10126, Italy
2Center for Experimental Research and Medical Studies, University Hospital Città della Salute e della Scienza di Torino, Torino 10126, Italy
3Department of Oncology, University of Turin, Turin 10126, Italy
4Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA
5Molecular Biotechnology Center, Turin 10126, Italy
6Immunogenetics and Transplantation Biology Service, University Hospital Città della Salute e della Scienza di Torino, Torino 10126, Italy
7Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
8Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
*These authors contributed equally to this work
Francesco Novelli, e-mail: [email protected]
Keywords: alpha-enolase, cancer metabolism, Warburg effect, cellular senescence
Received: July 18, 2015 Accepted: December 05, 2015 Published: December 30, 2015
In the last 5 years, novel knowledge on tumor metabolism has been revealed with the identification of critical factors that fuel tumors. Alpha-enolase (ENO1) is commonly over-expressed in tumors and is a clinically relevant candidate molecular target for immunotherapy. Here, we silenced ENO1 in human cancer cell lines and evaluated its impact through proteomic, biochemical and functional approaches. ENO1 silencing increased reactive oxygen species that were mainly generated through the sorbitol and NADPH oxidase pathways, as well as autophagy and catabolic pathway adaptations, which together affect cancer cell growth and induce senescence. These findings represent the first comprehensive metabolic analysis following ENO1 silencing. Inhibition of ENO1, either alone, or in combination with other pathways which were perturbed by ENO1 silencing, opens novel avenues for future therapeutic approaches.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.